The Serum High-Sensitive C Reactive Protein and Homocysteine Levels to Evaluate the Prognosis of  Acute Ischemic Stroke

Yoldas, Tahir; Gonen, Murat; Godekmerdan, Ahmet; Ilhan, Fulya; Bayram, Ednan

doi:https://doi.org/10.1155/2007/15929

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Clinical Study | Open Access

Volume 2007 | Article ID 015929 | https://doi.org/10.1155/2007/15929

The Serum High-Sensitive C Reactive Protein and Homocysteine Levels to Evaluate the Prognosis of Acute Ischemic Stroke

Tahir Yoldas,¹Murat Gonen,¹Ahmet Godekmerdan,²Fulya Ilhan,²and Ednan Bayram³

Received14 Dec 2006

Accepted08 Feb 2007

Published11 Mar 2007

Abstract

Ischemic stroke is one of the most common causes of death worldwide and is most often caused by thrombotic processes. We investigated the changes in hsCRP and homocysteine levels, two of these risk factors, during the acute period of ischemic stroke and evaluated the relationship between these levels and the short-term prognosis. HsCRP and homocysteine levels were measured at the 2nd, 5th, and 10th days in forty patients admitted within second of an ischemic stroke. The clinical status of the patients was simultaneously evaluated with the Scandinavian stroke scale. The results were compared with 40 healthy control subjects whose age and sex were matched with the patients. The mean hsCRP levels of the patients were 9.4±7.0 mg/L on the 2nd day, 11.0±7.4 mg/L on the 5th day, and 9.2±7.0 mg/L on the 10th day. The mean hsCRP level of the control subjects was 1.7±2.9 mg/L. The mean hsCRP levels of the patients on the 2nd, 5th, and 10th days were significantly higher than the control subjects (P<.001). The patients' mean homocysteine levels were 40.6±9.6μmol/L on the 2nd day, 21.7±11.1μmol/L on the 5th day, and 20.7±9.2μmol/L on the 10th day. The mean homocysteine level of the control subjects was 11.2±1.1μmol/L. The homocysteine levels of the patients were higher than the control subjects at all times (P<.01). In conclusion, patients with stroke have a higher circulating serum hsCRP and homocysteine levels. Short-term unfavorable prognosis seems to be associated with elevated serum hsCRP levels in patients with stroke. Although serum homocysteine was found to be higher, homocysteine seems not related to prog nosis.

References

J. A. Zivin, “Factors determining the therapeutic window for stroke,” Neurology, vol. 50, no. 3, pp. 599–603, 1998.
View at: Google Scholar
W.-D. Heiss, A. Thiel, M. Grond, and R. Graf, “Which targets are relevant for therapy of acute ischemic stroke?” Stroke, vol. 30, no. 7, pp. 1486–1489, 1999.
View at: Google Scholar
A. Furlan, R. Higashida, L. Wechsler et al., “Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism,” Journal of the American Medical Association, vol. 282, no. 21, pp. 2003–2011, 1999.
View at: Publisher Site | Google Scholar
S. M. Wolpert, H. Bruckmann, R. Greenlee, L. Wechsler, M. S. Pessin, and G. J. Del Zoppo, “Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA acute stroke study group,” American Journal of Neuroradiology, vol. 14, no. 1, pp. 3–13, 1993.
View at: Google Scholar
T. J. DeGraba, “The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy,” Neurology, vol. 51, no. 3, supplement, pp. S62–S68, 1998.
View at: Google Scholar
I. S. Ockene, C. E. Matthews, N. Rifai, P. M. Ridker, G. Reed, and E. Stanek, “Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults,” Clinical Chemistry, vol. 47, no. 3, pp. 444–450, 2001.
View at: Google Scholar
P. M. Ridker, “High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease,” Circulation, vol. 103, no. 13, pp. 1813–1818, 2001.
View at: Google Scholar
N. Rifai and P. M. Ridker, “High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease,” Clinical Chemistry, vol. 47, no. 3, pp. 403–411, 2001.
View at: Google Scholar
N. S. Rost, P. A. Wolf, C. S. Kase et al., “Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study,” Stroke, vol. 32, no. 11, pp. 2575–2579, 2001.
View at: Google Scholar
G. J. Blake and P. M. Ridker, “Inflammatory bio-markers and cardiovascular risk prediction,” Journal of Internal Medicine, vol. 252, no. 4, pp. 283–294, 2002.
View at: Publisher Site | Google Scholar
R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
View at: Publisher Site | Google Scholar
V. Pasceri, J. T. Willerson, and E. T. H. Yeh, “Direct proinflammatory effect of C-reactive protein on human endothelial cells,” Circulation, vol. 102, no. 18, pp. 2165–2168, 2000.
View at: Google Scholar
L. H. Kuller, R. P. Tracy, J. Shaten, and E. N. Meilahn, “Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial,” American Journal of Epidemiology, vol. 144, no. 6, pp. 537–547, 1996.
View at: Google Scholar
R. S. Rosenson and W. Koenig, “High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease,” Current Opinion in Cardiology, vol. 17, no. 4, pp. 325–331, 2002.
View at: Publisher Site | Google Scholar
P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease,” Circulation, vol. 97, no. 5, pp. 425–428, 1998.
View at: Google Scholar
P. M. Ridker, S. S. Bassuk, and P. P. Toth, “C-reactive protein and risk of cardiovascular disease: evidence and clinical application,” Current Atherosclerosis Reports, vol. 5, no. 5, pp. 341–349, 2003.
View at: Google Scholar
G. Boysen, T. Brander, H. Christensen, R. Gideon, and T. Truelsen, “Homocysteine and risk of recurrent stroke,” Stroke, vol. 34, no. 5, pp. 1258–1261, 2003.
View at: Publisher Site | Google Scholar
J. Selhub, P. F. Jacques, A. G. Bostom et al., “Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis,” New England Journal of Medicine, vol. 332, no. 5, pp. 286–291, 1995.
View at: Publisher Site | Google Scholar
J. W. Eikelboom, G. J. Hankey, S. S. Anand, E. Lofthouse, N. Staples, and R. I. Baker, “Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke,” Stroke, vol. 31, no. 5, pp. 1069–1075, 2000.
View at: Google Scholar
P. J. Kelly, J. Rosand, J. Kistler et al., “Homocysteine, MTHFR 677C $?$ T polymorphism, and risk of ischemic stroke: results of a meta-analysis,” Neurology, vol. 59, pp. 529–536, 2002.
View at: Google Scholar
C. J. Smith, H. C. Emsley, C. M. Gavin et al., “Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome,” BMC Neurology, vol. 4, no. 1, p. 2, 2004.
View at: Publisher Site | Google Scholar
N. B. Beamer, B. M. Coull, W. M. Clark, J. S. Hazel, and J. R. Silberger, “Interleukin-6 and interleukin-1 receptor antagonist in acute stroke,” Annals of Neurology, vol. 37, no. 6, pp. 800–805, 1995.
View at: Publisher Site | Google Scholar
N. J. Rothwell and J. K. Relton, “Involvement of cytokines in acute neurodegeneration in the CNS,” Neuroscience and Biobehavioral Reviews, vol. 17, no. 2, pp. 217–227, 1993.
View at: Publisher Site | Google Scholar
M. Chopp, R. L. Zhang, H. Chen, Y. Li, N. Jiang, and J. R. Rusche, “Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats,” Stroke, vol. 25, no. 4, pp. 869–875, 1994.
View at: Google Scholar
N. Jiang, M. Moyle, H. R. Soule, W. E. Rote, and M. Chopp, “Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats,” Annals of Neurology, vol. 38, no. 6, pp. 935–942, 1995.
View at: Publisher Site | Google Scholar
K. W. Muir, C. J. Weir, W. Alwan, I. B. Squire, and K. R. Lees, “C-reactive protein and outcome after ischemic stroke,” Stroke, vol. 30, no. 5, pp. 981–985, 1999.
View at: Google Scholar
M. Di Napoli, F. Papa, and V. Bocola, “C-reactive protein in ischemic stroke: an independent prognostic factor,” Stroke, vol. 32, no. 4, pp. 917–924, 2001.
View at: Google Scholar
J. C. Chambers, A. McGregor, J. Jean-Marie, O. A. Obeid, and J. S. Kooner, “Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy,” Circulation, vol. 99, no. 9, pp. 1156–1160, 1999.
View at: Google Scholar
F. Nappo, N. De Rosa, R. Marfella et al., “Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins,” Journal of the American Medical Association, vol. 281, no. 22, pp. 2113–2118, 1999.
View at: Publisher Site | Google Scholar
J.-H. Yoo, C.-S. Chung, and S.-S. Kang, “Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis,” Stroke, vol. 29, no. 12, pp. 2478–2483, 1998.
View at: Google Scholar
D. J. Meiklejohn, M. A. Vickers, R. Dijkhuisen, and M. Greaves, “Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke,” Stroke, vol. 32, no. 1, pp. 57–62, 2001.
View at: Google Scholar
A. Lindgren, L. Brattstrom, B. Norrving, B. Hultberg, A. Andersson, and B. B. Johansson, “Plasma homocysteine in the acute and convalescent phases after stroke,” Stroke, vol. 26, no. 5, pp. 795–800, 1995.
View at: Google Scholar
M. Ribó, J. Montaner, J. Monasterio et al., “Role of homocysteine in the acute phase of stroke,” Neurologia, vol. 19, no. 1, pp. 10–14, 2004.
View at: Google Scholar
J. Pniewski, M. Chodakowska-Zebrowska, R. Woźniak, K. Stępień, and A. Stafiej, “Plasma homocysteine level and the course of ischemic stroke,” Acta Neurobiologiae Experimentalis, vol. 63, no. 2, pp. 127–130, 2003.
View at: Google Scholar

Copyright

Copyright © 2007 Tahir Yoldas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

383

Downloads

905

Citations